Please assess the completion status of the following clinical trial:

Trial Title: A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Provide signed written informed consent~* Diagnosis of POAG or OHT in both eyes~* Qualifying corrected visual acuity in each eye~* Qualifying central corneal thickness in each eye~* Qualifying Day 1 IOP measurement at 3 time-points in both eyes~* Qualifying Anterior chamber angle~Exclusion Criteria:~* History of ocular surgery specifically intended to lower IOP~* Subjects who cannot safely discontinue use of ocular hypotensive medications during the wait/washout period~* Advanced glaucoma in either eye~* Any corneal abnormality or other condition interfering with or preventing reliable Goldmann applanation tonometry~* Any ocular surgery or ocular laser treatment within 90 days prior to Visit 1 (Screening) and throughout the study in either eye~* Females who are pregnant, nursing, or planning a pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Vehicle of DE-126) followed by high dose of DE-126 (Type: PLACEBO_COMPARATOR): None
- Ultra-low dose 0.0005% DE-126 (Type: EXPERIMENTAL): None
- Low dose 0.001% DE-126 (Type: EXPERIMENTAL): None
- Medium dose 0.002% DE-126 (Type: EXPERIMENTAL): None
- High dose 0.003% DE-126 (Type: EXPERIMENTAL): None
- 0.005% Latanoprost (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).